Form 4: Lyell Immunopharma Director William J.L. Rieflin Acquires 130,000 Stock Options
SEC Form 4 Filing
Director William J.L. Rieflin acquired 130,000 stock options in Lyell Immunopharma, Inc. on May 15, 2025.
Summary
- On May 15, 2025, William J.L. Rieflin, a director of Lyell Immunopharma, Inc., acquired 130,000 stock options.
- The exercise price of these options is $0.4017.
- The options vest on the earlier of the next annual meeting of stockholders after May 15, 2025, or the first anniversary of May 15, 2025, contingent upon continuous service.
- The options expire on May 14, 2035.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock option grant to a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the transaction: acquisition of 130,000 stock options. |
| 05/15/2025 | Date from which the options vest, either at the next annual stockholder meeting or on the first anniversary. |
| 05/14/2035 | Expiration date of the stock options. |
Keywords
Lyell Immunopharma, Director, Stock Options, Beneficial Ownership, Form 4, Rieflin, LYEL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.